The news from Quanterix Corp. has come fast and furiously this week. The company reported that Chairman and CEO Kevin Hrusovsky will step down on April 25 and become executive chairman of the board, while current company President Masoud Toloue will assume the CEO position and join the board of directors. Hrusovsky became CEO in 2014 and Toloue joined Quanterix in June 2021 from Perkinelmer Inc. The company also revealed that it has built on its collaboration with Indianapolis-based Eli Lilly and Co. for new tools to diagnose, monitor and treat Alzheimer’s disease (AD) and presented its fiscal 2021 financial results, which showed a 28% increase in total revenue, largely attributable to its neurology segment.
Related Posts
Spatial Analysis
Snapshots of Health Innovation From the Edison Awards
Building the Tools Parkinson’s Disease Research Needs
A Q&A with Kishore Malyavantham, PhD, VP of R&D at Quanterix and Co-Investigator, PD-BUILD Quanterix has been named a Co-Investigator institution in PD-BUILD (Biomarker Utilization, Innovation, and Laboratory-to-Deployment), a new project…
Quanterix Named to ASAP CRN 2026 PD-BUILD Program with MJFF Support
Part of a global effort to advance Parkinson’s disease biomarkers through standardized, scalable assay development Quanterix has been selected as a Co-Investigator institution in the PD-BUILD program, part of the…
Neurology
Why biomarkers are no longer supplemental
Quanterix makes the case with ctDNA in oncology, p-tau217 in Alzheimer’s and a lab model built for longitudinal, regulatory-grade data. Biomarkers have moved from “nice-to-have” to the backbone of drug…
Neurology
Preparing The Market for Blood-Based Biomarkers
Shana Tetrault, PhD, Director of Product Marketing at Quanterix, outlined strategies for integrating blood-based biomarkers into routine clinical care pathways, ensuring minimal disruption for patients and clinicians. Watch the full…
Neurology
Challenges of Positioning an Ultra-Sensitive Platform
Shana Tetrault, PhD, Director of Product Marketing at Quanterix, discussed challenges in positioning Simoa in the precision health market, stressing its accuracy and reliability in diverse populations. Watch the full…
Neurology
Translating Complex Scientific Findings into Actionable Insights
Shana Tetrault, PhD, Director of Product Marketing at Quanterix, discussed translating complex scientific findings into actionable insights for healthcare providers and stakeholders, emphasizing the importance of early disease detection. Watch…
Neurology
AI and the rise of blood-based biomarkers heralds new era for neurological diagnostics
Advances in blood-based biomarkers are transforming early and accurate Alzheimer’s disease detection, offering less invasive, cost-effective alternatives to traditional diagnostic methods. Quanterix, a company working at the very frontiers of…